Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Stem-cell boss urges communication

Nature (2011)Cite this article

Subjects

Incoming chairman wants public to know about California stem-cell agency's work.

On 22 June, the board of the California Institute for Regenerative Medicine (CIRM) in San Francisco selected financier Jonathan Thomas as its next chairman. Thomas replaces Robert Klein, who wrote and led the campaign for Proposition 71, the California state law that created the institute, and who played an huge part in all aspects of the agency during his incumbency (see 'Stem cells: The impatient advocate'). Thomas takes over during an ongoing state budget crisis; Nature spoke to him about his plans for navigating this and other challenges.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Erika Check Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Follow Erika on Twitter at @Erika_Check.

Related links

Related links

Related links in Nature Research

California's stem cell agency to choose between investment banker and cardiologist

Related external links

California Institute for Regenerative Medicine

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Check Hayden, E. Stem-cell boss urges communication. Nature (2011). https://doi.org/10.1038/news.2011.390

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/news.2011.390

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research